Fourth Quarter & Full Year 2022 Financial & Business Update
Within our Clinical Pipeline we Prioritized Those Which Are Most
Differentiated and Provide the Greatest Potential
Commercial
Portfolio
&
ADCETRIS
brentuximab vedotin | for injection
PADCEV
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials
ADC PLATFORM
Late-Stage
Pipeline
Disitamab Vedotin¹
SGN-B6A
Ladiratuzumab Vedotin²
SGN-B7H4V
tivdak
tisotumab vedotin-tfty
for injection 40 mg
Q
TUKYSA
tucatinib
50 mg 150 mg tablets
OTHER TARGETED MODALITIES
SEA-TGT
SGN-STNV
Early-Stage
Pipeline
SGN-ALPV
SGN-PDL1V
SEA-CD705
Novel Payload ADCs³
SGN-BB2286
CEACAM5 ADC3,4
SGN-EGFRd23,7
Seagen
1 Remegen has rights for Asia excluding Japan and Singapore; 2 Co-development and co-commercialization agreement with Merck; 3 Represents programs expected to enter the clinic by YE23; 4 50-50 profit share
arrangement with Sanofi; 5 BeiGene has rights outside of the Americas, Europe and Japan for SEA-CD70; 6 Pieris has right to copromote one product; 7 Also known as LAVA-1223
10
10View entire presentation